【摘要】 目的:观察外周血白细胞(WBC)计数在2型糖尿病患者中的水平及其影响因素,并应用罗格列酮进行干预治疗,探讨罗格列酮的血管保护作用。方法:75例2型糖尿病患者应用罗格列酮4mg/d治疗,共12周,治疗前、后与55例正常对照组患者比较血糖相关指标、血压、血脂谱、vWF及WBC。结果:治疗前糖尿病组WBC(6.58±1.64)×109高于对照组WBC(5.34±0.95)×109,(P<0.05)。治疗后,血糖、糖化血红蛋白(Hb)A1c、稳态模型-胰岛素抵抗指数(HOMA-IR)、血压、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)、vWF及WBC计数均下降(P<0.05)。以WBC计数中位数(6.4×109)分组进行相关分析,WBC计数与腰围、BMI呈正相关,WBC计数高于中位数组的腰围、BMI、TC、vWF也高于WBC低于中位数组(P<0.05)。结论:慢性亚临床炎症可能参与2型糖尿病的发生及发展。罗格列酮除降糖、改善胰岛素抵抗、调脂、降压外,还发挥抗炎、抗内皮细胞损伤的作用。更多还原

【Abstract】 Objective:To evaluate the relationship between white blood cell count and type 2 diabetes mellitus and investigate the mechanisms of the protective effects of rosiglitazone. Methods: 75 type 2 diabetic patients received rosiglitazone (4 mg/d) for 12 weeks. WBC count and other clinical parameters were determined at baseline and after 12 weeks and in 55 normal controls. Results: In the diabetic patients, WBC were markedly higher (6.58±1.64)×109 as compared with normal controls (5.34±0.95)×109, (P<0.05). After treatment with rosiglitazone for 12 weeks, blood glucose,HbA1c,HOMA-IR,blood pressure, TC, TG, LDL-C, vWF and WBC (P<0.05) were significantly reduced. WBC was positively correlated to waist (r=0.397), BMI (r=0.255), respectively (P<0.05). Diabetic patients were divided into two groups according to median of WBC:W1 (<6.4×109)group, W2 (>6.4×109) group. Compared with W1 group,Waist, BMI, TC and vWF were elevated in W2 group (P<0.05). Conclusion: Chronic subclinical inflammation may play a role in the pathogenesis of type 2 diabetes. Rosiglitazone has anti-inflammatory effects and can improve endothelial function except lowering blood glucose, improving insulin resistance, regulating lipid metabolism and blood pressure.更多还原